The role of blood pressure as a risk factor for renal disease: A review of the epidemiologic evidence

Journal of Human Hypertension

Volumn 10, Issue 10, 1996, Pages 683-689

  Whelton, P K ^a,c   Perneger, T V ^b   He, J ^a   Klag, M J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c NONE   (United States)

Author keywords

Blood pressure; End stage renal disease; Epidemiology; Prevention; Renal disease

Indexed keywords

ADULT; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CASE CONTROL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; HUMANS; KIDNEY DISEASES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030449088     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. US Renal Data System, USRDS 1995 Annual Data Report: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Besthesa, MD, April 1995.
2. Whelton PK, Brancati F, Appel LJ, Klag MJ. The challenge of hypertension and atherosclerotic cardiovascular disease in economically developing countries. High Blood Pressure and Cardiovascular Prevention 1995; 4: 36-45.
3. Whelton PK. The evolving epidemic of cardiovascular and renal diseases: a worldwide challenge. Curr Opin Nephrol Hypertens 1995; 4: 215-217.
4. Perneger TV, Brancati FL, Whelton PK, Klag MJ. Studying the causes of kidney disease in humans: a review of methodologic obstacles and possible solutions. Am J Kidney Dis 1995; 25: 722-731.
5. Whelton PK, Klag MJ. Hypertension as a risk factor for renal disease: review of clinical and epidemiological evidence. Hypertension 1989; 13: 1-19.
6. Perneger TV et al. A prospective study of blood pressure and serum creatinine: results from the 'CLUE' study and the ARIC study. JAMA 1993; 269: 488-493.
7. Shulman NB et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: results from the Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (Suppl 1): 1-80-1-93.
8. Rostand SG et al. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 321: 1074-9.
9. Walker WG et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA 1992; 286: 3085-3091.
10. Brancati FL, Whelton PK, Whittle JC, Klag MJ. Epidemiologic analysis of existing data to investigate hypertensive renal disease: an example from the Maryland ESRD Registry. Am J Kidney Dis 1993; 21 (Suppl 1): 15-24.
11. Whelton PK, Klag MJ, Perneger T. Prevention of blood pressure-related kidney failure: an epidemiological perspective. Seminars in Dialysis 1993; 6: 84-86.
12. Klag MJ et al. A prospective study of blood pressure and incidence of end-stage renal disease in 332,544 men. N Engl J Med 1996; 334: 13-18.
13. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121: 912-918.
14. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal anti-inflammatory drugs. N Engl J Med 1994; 331: 1675-1679.
15. Perneger TV, Whelton PK, Klag MJ. Race and end-stage renal disease: socio-economic status and access to health care as mediating factors. Arch Intern Med 1995; 155: 1201-1208.
16. Whittle JC, Whelton PK, Klag MJ, Seidler AJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end stage renal disease. Arch Intern Med 1991; 151: 1359-1364.
17. Perneger TV, Klag MJ, Whelton PK. Race and socioeconomic status in hypertension and renal disease. Curr Opin Nephrol Hypertens 1995; 4: 235-239.
18. Perneger TV, Klag MJ, Feldman HI, Whelton PK. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 1993; 269: 1272-1277.
19. Whelton PK. Epidemiology of Hypertension. Lancet 1994; 344: 101-106.
20. Burt V et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-91. Hypertension 1995; 25: 305-313.
21. Whelton PK, Brancati F. Hypertension management in populations. Clin Exper Hypertens 1993; 15: 1147-1156.
22. Apostolides AY, Su SI, Shankar B, Shapiro S. Quality control for data gathering by the Maryland Hypertension Survey. In: Proceedings of the Section of Survey Research Methods. Washington DC: Am Stat Assoc 1980; 692-694.
23. Whelton PK, Perneger TV, Brancati FL, Klag MJ. Epidemiology and prevention of blood pressure-related renal disease. J Hypertens 1992; 10 (Suppl 7): S77-S84.
24. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and non-hypertensive subjects. Arch Intern Med 1990; 150: 2073-2076.
25. Perneger TV. Case-control study of risk factors for end-stage renal disease. Ph.D. Dissertation; Johns Hopkins University, Baltimore, Maryland, 1993.
26. Perry HM Jr et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25: 587-94.
27. Zuchelli P et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-458.
28. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
29. Maschio G et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
30. Klahr S et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
31. Kusek JW et al. Study design of the pilot phase of the African American Study of Kidney Disease and Hypertension (AASK). Controlled Clin Trials 1994; 15 (Suppl 3): 133S.
32. Schrier RW, Savage S. Appropriate blood pressure control in type II diabetes (ABCD) trial: implications for complications. Am J Kid Dis 1992; 6: 653-657.
33. Davis BR et al for the ALLHAT Research Group. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-360.
34. Whelton PK et al for the ALLHAT Research Group. Experimental approaches to determining the choice of first step therapy for patients with hypertension. Clin Exper Hypertens 1996; 18: 569-579.
35. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154-183.
36. Burt VL et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population: data from Health Examination Surveys 1960-1991. Hypertension 1995; 26: 60-69.
37. Ibrahim MM et al for the NHP Investigative Team. Hypertension Prevalence, Awareness, Treatment and Control in Egypt: Results from the Egyptian National Hypertension Project (NHP). Hypertension 1995; 26: 886-890.
38. He J, Klag MJ, Zhenglai W, Whelton PK. Stroke in the People's Republic of China. I. Geographic variations in incidence and risk factors. Stroke 1995; 26: 2222-2227.
39. He J, Klag MJ, Zhenglai W, Whelton PK. Stroke in the People's Republic of China. II. Meta-analysis of hypertension and risk of stroke. Stroke 1995; 26: 2228-2232.
40. Whelton PK. Primary prevention of hypertension: rationale, approaches, realities and perspectives. J Hum Hypertens 1996; 10 (Suppl 1): S47-S50.
41. Working Group on Primary Prevention of Hypertension. Report of the National High Blood Pressure Education Program Working Group on Primary Prevention of Hypertension. Arch Intern Med 1993; 153: 186-208.
42. Klag MJ, Whelton PK, Appel LJ. Effect of age on the efficacy of blood pressure treatment strategies. Hypertension 1990; 16: 700-705.
43. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615.
44. Cook NR et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155: 701-709.